Investment Rating - The report indicates that the cosmetics and medical beauty sector is currently underperforming compared to the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the overall market performance [1][2]. Core Insights - 毛戈平 has initiated an international strategic partnership with L Catterton, a leading global consumer investment firm, focusing on global market expansion, acquisitions, strategic investments, capital structure optimization, and talent introduction [1][6][17]. - The approval of products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies ongoing advancements in the medical beauty supply chain, enhancing competitive diversity for 2026 [1][6][18][19]. - The report highlights the robust foundation of 壹网壹创's e-commerce operations, leveraging AI to enhance performance and expand its market reach, particularly in the consumer goods sector [1][7][8][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with specific indices underperforming against the Shenwan A Index [2][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the underperformers include 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [2][5]. Recent Developments - 毛戈平's strategic collaboration with L Catterton aims to enhance its brand's presence in high-end retail channels globally and establish a joint investment fund focused on premium beauty products [1][6][17]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant reflects a significant push in the medical beauty equipment supply chain, contributing to competitive advantages in the upcoming year [1][6][18][19]. E-commerce Insights - 壹网壹创's e-commerce operations are well-established, with a comprehensive coverage of consumer goods categories and a strong partnership with Alibaba, which is expected to drive revenue growth through AI integration [1][7][8][10]. - The e-commerce sector is witnessing a resurgence in attention, with Alibaba's platform traffic rebounding, indicating a potential recovery in the performance of e-commerce operations [1][8][10]. Market Data - The report notes that the retail sales of cosmetics in China for November 2025 grew by 6.1%, supported by promotional events like Double 11, indicating a robust recovery in consumer spending [13][15]. - The overall retail sales of consumer goods in China reached 45.6 trillion yuan in the first eleven months of 2025, with a year-on-year growth of 4.0% [13][15].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][3]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the Shenwan A Index by 2.8 percentage points [3][4]. - 毛戈平 has initiated an international strategic partnership with L Catterton, focusing on global market expansion, acquisitions, and strategic investments, which is expected to enhance its high-end retail channels and operational optimization [9][21]. - Recent approvals for products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant highlight the ongoing advancements in the medical beauty supply chain, supporting diversified competition in 2026 [9][22][23]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing lower growth rates compared to the overall market [3][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the worst performers were 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [5]. Recent Developments - 毛戈平's strategic partnership with L Catterton aims to enhance its brand's global presence and operational capabilities [9][21]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies a robust supply chain in the medical beauty sector [22][23]. Investment Recommendations - Recommended companies include 毛戈平, 上美股份, and 上海家化 for their strong brand matrices and growth potential. Companies like 爱美客 and 朗姿股份 are highlighted for their strong profitability and product pipeline [3][10]. - The report suggests focusing on companies with high R&D barriers and strong profitability in the upstream medical beauty segment [3][10].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 0.2% from December 26 to December 31, 2025, while the Shenwan Cosmetics Index increased by 1.0% [4][5]. - Lin Qingxuan successfully completed its IPO on December 30, 2025, attracting significant investor attention. The company, founded in 2003, reported a revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate (CAGR) of 32.7% [4][10]. - Upward confidence in the company is reflected in the share buyback by senior management at Shangmei Co., with a total of 835,900 shares purchased in December 2025, amounting to approximately 66.32 million HKD [4][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector showed strong performance, with the Shenwan Beauty Care Index increasing by 0.2% during the specified period, outperforming the market [4][5]. - The top-performing stocks included Yanjiang Co. (+14.3%), Shuiyang Co. (+9.5%), and Qingsong Co. (+7.0%), while Shangmei Co. saw a decline of 18.6% [6]. Key Company Updates - Lin Qingxuan's IPO on the Hong Kong Stock Exchange was a significant event, marking it as a leading high-end domestic skincare brand. The company has a strong market presence with a focus on camellia oil-based products [4][10]. - Shangmei Co. demonstrated management confidence through share buybacks, indicating a positive outlook for future growth [4][10]. E-commerce and AI Integration - The report highlights the robust foundation of the e-commerce agency business, particularly for companies like Yiwan Yichuang, which is leveraging AI to enhance operational efficiency and performance [11][12]. - The e-commerce agency sector is experiencing a resurgence, driven by increased demand for brand representation on platforms like Alibaba [12][13]. Market Data - The retail sales of cosmetics in China for the first eleven months of 2025 reached 428.5 billion yuan, reflecting a year-on-year growth of 4.8% [16]. - The report indicates that the market for PDRN components is expected to reach 285 million USD globally by 2029, with China projected to capture 34% of this market [21]. Competitive Landscape - The domestic skincare market is becoming increasingly competitive, with local brands gaining market share against international competitors. The report notes that local brands now occupy five of the top ten positions in market share [24]. - The report anticipates that the trend of domestic brands gaining market share will continue, particularly in the context of rising consumer preference for local products [24].

Investment Rating - The report indicates a cautious outlook for the cosmetics and medical beauty sector, with the beauty care index declining by 1.1% from December 19 to December 26, 2025, underperforming the market [3][4]. Core Insights - Lin Qingxuan is set to lead the high-end domestic essence oil market with its upcoming IPO on December 30, 2025, aiming to issue 13.9665 million H shares. The brand has established itself as a benchmark in high-end domestic skincare, with a market share of 1.4% in 2024, ranking 13th among high-end skincare brands [3][8]. - The company has shown impressive growth, with revenue increasing from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7%. The net profit margin for the first half of 2025 reached 17.3%, with net profit doubling to 182 million yuan year-on-year [3][8]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with the cosmetics index down 1.3%, lagging behind the Shenwan A index by 4.2 percentage points [3][4]. - The top-performing stocks in the sector included Yanjiang Co. (+10.9%), Mingchen Health (+9.2%), and Hongmian Co. (+8.6%), while the worst performers were Nobon Co. (-4.0%), Mengyue Care (-3.4%), and Shangmei Co. (-3.1%) [4]. Key Company Updates - Yiwang Yichuang (300792SZ) is highlighted for its robust operational foundation in e-commerce agency services, leveraging AI to enhance performance. The company has seen a turnaround in net profit growth, with a 4% year-on-year increase in the first three quarters of 2025 [9][10]. - The approval of Jiangsu Chuangjian Medical's "cross-linked recombinant collagen implant" on December 24, 2025, marks a significant advancement in the medical beauty sector, targeting facial dermal filling [19][21]. Market Trends - The retail sales of cosmetics in China for the first eleven months of 2025 reached 428.5 billion yuan, with a year-on-year growth of 4.8%. The sales in November alone grew by 6.1%, driven by promotional events [16][20]. - The report notes a shift in market dynamics, with domestic brands gaining market share against international competitors. In 2024, the domestic skincare market is projected to reach 271.2 billion yuan, despite a decline of 3.7% year-on-year [24][26].